Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002734
Status:
COMPLETED
Last Update Posted:
2013-02-05
First Post:
1999-11-01
Brief Title:
Radiolabeled Monoclonal Antibody Paclitaxel and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
PHASE I STUDY OF INTERFERON ENHANCED INTRAPERITONEAL RADIOIMMUNO-CHEMOTHERAPY FOR OVARIAN CANCER
Status:
COMPLETED
Status Verified Date:
2001-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody paclitaxel and interferon alfa in treating patients who have ovarian cancer Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Interferon may interfere with the growth of cancer cells Combining monoclonal antibody chemotherapy and interferon alfa may kill more tumor cells
Detailed Description:
OBJECTIVES
I Determine the maximum tolerated dose MTD of intraperitoneal paclitaxel and topotecan when administered as a radiosensitizer prior to intraperitoneal lutetium Lu 177 monoclonal antibody CC49 177Lu-CC49 following subcutaneous interferon alfa-2b IFN-A in patients with persistent or recurrent ovarian cancer
II Determine the toxicity associated with intraperitoneal paclitaxel and topotecan in these patients
III Examine the conjugate stability pharmacokinetics and biodistribution of 177Lu-CC49 given 48 hours after intraperitoneal paclitaxel
IV Determine the effects of IFN-A and intraperitoneal paclitaxel on 177Lu-CC49 tumor localization and dosimetry estimates compared to a prior trial with 177Lu-CC49 alone
V Determine the MTD of yttrium Y 90 monoclonal antibody CC49 90Y-CC49 when administered with IFN-A and the dose of paclitaxel used at the MTD level of IFN-A paclitaxel and 177Lu-CC49
VI Monitor any antitumor effects of this treatment in these patients
OUTLINE This is a dose escalation study of paclitaxel topotecan lutetium LU 177 monoclonal antibody CC-49 177Lu-CC49 and yttrium Y 90 monoclonal antibody CC49 90Y-CC49
Patients receive interferon alfa subcutaneously on days 1 3 5 and 7 paclitaxel intraperitoneally IP on day 4 or topotecan IP on day 6 and 177Lu-CC49 IP on day 6 Treatment continues every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity Cohorts of 3-5 patients receive escalating doses of paclitaxel and decreasing doses of 177Lu-CC49 until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 3 of 5 patients experience dose limiting toxicity Once the MTD of paclitaxel is determined the dose of 177Lu-CC49 is escalated Once the MTD of 177Lu-CC49 is determined 90Y-CC49 is substituted The MTD of 90Y-CC49 is then determined when administered with paclitaxel Topotecan is then substituted for paclitaxel administered with the MTD of 177Lu-CC49 and interferon alfa only and escalated until the MTD is determined Patients are followed at 6 weeks and then every 3 months for 1 year
I Determine the maximum tolerated dose MTD of intraperitoneal paclitaxel and topotecan when administered as a radiosensitizer prior to intraperitoneal lutetium Lu 177 monoclonal antibody CC49 177Lu-CC49 following subcutaneous interferon alfa-2b IFN-A in patients with persistent or recurrent ovarian cancer
II Determine the toxicity associated with intraperitoneal paclitaxel and topotecan in these patients
III Examine the conjugate stability pharmacokinetics and biodistribution of 177Lu-CC49 given 48 hours after intraperitoneal paclitaxel
IV Determine the effects of IFN-A and intraperitoneal paclitaxel on 177Lu-CC49 tumor localization and dosimetry estimates compared to a prior trial with 177Lu-CC49 alone
V Determine the MTD of yttrium Y 90 monoclonal antibody CC49 90Y-CC49 when administered with IFN-A and the dose of paclitaxel used at the MTD level of IFN-A paclitaxel and 177Lu-CC49
VI Monitor any antitumor effects of this treatment in these patients
OUTLINE This is a dose escalation study of paclitaxel topotecan lutetium LU 177 monoclonal antibody CC-49 177Lu-CC49 and yttrium Y 90 monoclonal antibody CC49 90Y-CC49
Patients receive interferon alfa subcutaneously on days 1 3 5 and 7 paclitaxel intraperitoneally IP on day 4 or topotecan IP on day 6 and 177Lu-CC49 IP on day 6 Treatment continues every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity Cohorts of 3-5 patients receive escalating doses of paclitaxel and decreasing doses of 177Lu-CC49 until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 3 of 5 patients experience dose limiting toxicity Once the MTD of paclitaxel is determined the dose of 177Lu-CC49 is escalated Once the MTD of 177Lu-CC49 is determined 90Y-CC49 is substituted The MTD of 90Y-CC49 is then determined when administered with paclitaxel Topotecan is then substituted for paclitaxel administered with the MTD of 177Lu-CC49 and interferon alfa only and escalated until the MTD is determined Patients are followed at 6 weeks and then every 3 months for 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000064633 | REGISTRY | PDQ Physician Data Query | None |
| UAB-9502 | None | None | None |
| NCI-B95-0003 | None | None | None |